Cargando…

Trophoblast-Targeted Nanomedicine Modulates Placental sFLT1 for Preeclampsia Treatment

The overexpressed soluble fms-like tyrosine kinase 1 (sFLT-1) in placenta is considered to be a potential therapeutic target for preeclampsia (PE). How to achieve efficient intervention of sFLT1 expression in the placenta is an urgent problem to be solved. PEG-PLA nanoparticle generated by double-em...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Lei, Yang, Huijun, Chen, Pengzheng, Xin, Tao, Zhou, Qian, Wei, Dan, Zhang, Yanan, Wang, Shan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Bioengineering and Biotechnology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026029/ https://www.ncbi.nlm.nih.gov/pubmed/32117942 http://dx.doi.org/10.3389/fbioe.2020.00064

Ejemplares similares

RNAi Modulation of Placental sFLT1 for the Treatment of Preeclampsia.
por: Turanov, Anton A., et al.
Publicado: (2018)

Difference of concentration of placental soluble fms-like tyrosine kinase-1(sFlt-1), placental growth factor (PlGF), and sFlt-1/PlGF ratio in severe preeclampsia and normal pregnancy
por: Gurnadi, Jeffry Iman, et al.
Publicado: (2015)

Efficiency of sFlt-1/PlGF Ratio in Preeclampsia Diagnosis
por: Tataru-Copos, Anca-Florina, et al.
Publicado: (2022)

Predicting Preeclampsia Pregnancy Termination Time Using sFlt-1
por: Tanaka, Hiroaki, et al.
Publicado: (2022)

Deconvolution of a Large Cohort of Placental Microarray Data Reveals Clinically Distinct Subtypes of Preeclampsia
por: Yao, Tian, et al.
Publicado: (2022)

Preeclamptic Women Have Disrupted Placental microRNA Expression at the Time of Preeclampsia Diagnosis: Meta-Analysis
por: Cirkovic, Andja, et al.
Publicado: (2021)

A simple detection method for the serum sFLT1 protein in preeclampsia
por: Shibuya, Masabumi, et al.
Publicado: (2021)

Correlation of sFlt/PlGF ratio with severity of preeclampsia in an Indian population
por: Kumar, Namrata, et al.
Publicado: (2023)

MIF Increases sFLT1 Expression in Early Uncomplicated Pregnancy and Preeclampsia
por: Yong, Qing, et al.
Publicado: (2023)

Nanomedicine of Plant Origin for the Treatment of Metabolic Disorders
por: Hu, Fang, et al.
Publicado: (2022)

Fluidic Flow Enhances the Differentiation of Placental Trophoblast-Like 3D Tissue from hiPSCs in a Perfused Macrofluidic Device
por: Deng, Pengwei, et al.
Publicado: (2022)

Unfractionated heparin displaces sFlt-1 from the placental extracellular matrix
por: Moore, Kyle H., et al.
Publicado: (2020)

First-Trimester Maternal Serum Levels of sFLT1, PGF and ADMA Predict Preeclampsia
por: Bian, Zheng, et al.
Publicado: (2015)

Full-Length Human Placental sFlt-1-e15a Isoform Induces Distinct Maternal Phenotypes of Preeclampsia in Mice
por: Szalai, Gabor, et al.
Publicado: (2015)

Theranostic Nanomedicine for Malignant Gliomas
por: d'Angelo, Michele, et al.
Publicado: (2019)

Nanomedicine in Lung Cancer Immunotherapy
por: Doroudian, Mohammad, et al.
Publicado: (2023)

The application of nanomedicine in clinical settings
por: Zhao, Qingsong, et al.
Publicado: (2023)

Circulating Levels of sFlt1 Splice Variants as Predictive Markers for the Development of Preeclampsia
por: Souders, Colby A., et al.
Publicado: (2015)

Diagnostic accuracy of sFlt1/PlGF ratio as a marker for preeclampsia
por: Nikuei, Pooneh, et al.
Publicado: (2020)

Plant-Derived Nanovesicles: A Novel Form of Nanomedicine
por: Yu, Lanlan, et al.
Publicado: (2020)

Corrigendum: Theranostic Nanomedicine for Malignant Gliomas
por: d'Angelo, Michele, et al.
Publicado: (2020)

Editorial: Advanced Theranostic Nanomedicine in Oncology
por: Tapeinos, Christos, et al.
Publicado: (2020)

Nanomedicine for Imaging and Therapy of Pancreatic Adenocarcinoma
por: Brachi, Giulia, et al.
Publicado: (2019)

Nanomedicine for the Diagnosis and Therapy of COVID-19
por: Wang, Yingruo, et al.
Publicado: (2021)

Application of Nanomedicine in Inner Ear Diseases
por: Lin, Qianyu, et al.
Publicado: (2022)

Nanomedicines Targeting Metabolism in the Tumor Microenvironment
por: Ren, Mengdi, et al.
Publicado: (2022)

An immunoregulator nanomedicine approach for the treatment of tuberculosis
por: Yang, Luona, et al.
Publicado: (2023)

Placental and maternal sFlt1/PlGF expression in gestational diabetes mellitus
por: Nuzzo, Anna Maria, et al.
Publicado: (2021)

Chemical optimization of siRNA for safe and efficient silencing of placental sFLT1
por: Davis, Sarah M., et al.
Publicado: (2022)

Tumor Cell Distinguishable Nanomedicine Integrating Chemotherapeutic Sensitization and Protection
por: Liu, Sen, et al.
Publicado: (2021)

Nanomedicine: A Promising Way to Manage Alzheimer’s Disease
por: Khan, Nazeer Hussain, et al.
Publicado: (2021)

Nanomedicine Approaches for the Pulmonary Treatment of Cystic Fibrosis
por: Velino, Cecilia, et al.
Publicado: (2019)

Editorial: Emerging Advances in Bio-Nano Engineered Approaches Toward Intelligent Nanomedicine
por: Wang, Junqing, et al.
Publicado: (2021)

The sFlt-1/PlGF Ratio Trend Is Useful in Predicting Preeclampsia Severity in Hyperreactio Luteinalis Complicated with Preeclampsia
por: Miyatake, Risa, et al.
Publicado: (2023)

Increased sFlt-1 to PlGF Ratio in Women Who Subsequently Develop Preeclampsia
por: Kim, Shin-Young, et al.
Publicado: (2007)

Abnormal expression and clinical significance of 25-hydroxyvitamin D and sFlt-1 in patients with preeclampsia
por: Chen, Xinhua, et al.
Publicado: (2019)

Influential Serum Kinases (Non-sFlt-1) and Phosphatases in Preeclampsia—Systematic Review and Metanalysis
por: Marrufo-Gallegos, Karla Cecilia, et al.
Publicado: (2023)

Nanomedicines: A Potential Treatment for Blood Disorder Diseases
por: Zhang, Nan, et al.
Publicado: (2019)

Nanomedicines for Near-Infrared Fluorescent Lifetime-Based Bioimaging
por: Lian, Xianhui, et al.
Publicado: (2019)

A Methodological Safe-by-Design Approach for the Development of Nanomedicines
por: Schmutz, Mélanie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ppv87crf3idlfj37vi4l8hvi8j